Publications by authors named "Gerlinde Teuber"

Claim this Profile
I
Impact of distinct antiviral treatment regimens on the long-term outcome after HCV cure - Data from the German Hepatitis C-Registry (DHC-R).
Valerie Ohlendorf, Yvonne Serfert, Peter Buggisch, Stefan Mauss, Hartwig Klinker, Gerlinde Teuber

Z Gastroenterol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R).
Kathrin Krüger, Siegbert Rossol, Christian Krauth, Peter Buggisch, Stefan Mauss, Gerlinde Teuber

Z Gastroenterol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Markus Cornberg, Albrecht Stoehr, Uwe Naumann, Gerlinde Teuber, Hartwig Klinker

Viruses· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Kerstin Stein, Albrecht Stoehr, Hartwig Klinker, Gerlinde Teuber, Uwe Naumann

Eur J Gastroenterol Hepatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
Dietrich Hüppe, Albrecht Stoehr, Peter Buggisch, Stefan Mauss, Hartwig Klinker, Gerlinde Teuber

J Viral Hepat· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Johannes Vermehren, Yvonne Serfert, Markus Cornberg, Albrecht Stoehr, Hartwig Klinker, Gerlinde Teuber

Z Gastroenterol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Stefan Traussnigg, Jörn M Schattenberg, Münevver Demir, Johannes Wiegand, Andreas Geier, Gerlinde Teuber

Lancet Gastroenterol Hepatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Thomas Berg, Uwe Naumann, Albrecht Stoehr, Christoph Sick, Christine John, Gerlinde Teuber

Aliment Pharmacol Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
Peter Buggisch, Johannes Vermehren, Stefan Mauss, Rainer Günther, Eckart Schott, Gerlinde Teuber

J Hepatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
Benjamin Heidrich, Steffen B Wiegand, Peter Buggisch, Holger Hinrichsen, Ralph Link, Gerlinde Teuber

PLoS One· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients.
Georgios Grammatikos, Christian Lange, Simone Susser, Susanne Schwendy, Nektarios Dikopoulos, Gerlinde Teuber

PLoS One· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
Jona T Stahmeyer, Siegbert Rossol, Florian Bert, Christoph Antoni, Münevver Demir, Gerlinde Teuber

Eur J Gastroenterol Hepatol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Georg Dultz, Martin Seelhof, Eva Herrmann, Martin-Walter Welker, Mireen Friedrich-Rust, Gerlinde Teuber

PLoS One· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
Viola Knop, Gerlinde Teuber, Hartwig Klinker, Bernd Möller, Jens Rasenack

Ann Hepatol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Patrick Marcellin, Antonio Craxi, Carlos E Brandao-Mello, Adrian M Di Bisceglie, Pietro Andreone, Gerlinde Teuber

J Clin Gastroenterol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C.
Michael R Kraus, Arne Schäfer, Gerlinde Teuber, Heiner Porst, Kathrin Sprinzl

Hepatology· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.
Julia Dietz, Sven-Eric Schelhorn, Daniel Fitting, Ulrike Mihm, Simone Susser, Gerlinde Teuber

J Virol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
Johannes Wiegand, Konrad Neumann, Stephan Böhm, Viola Weich, Gerlinde Teuber

Clin Infect Dis· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Christoph Sarrazin, Susanne Schwendy, Bernd Möller, Nektarios Dikopoulos, Peter Buggisch, Gerlinde Teuber

Gastroenterology· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
Maria Buti, Yoav Lurie, Natalia G Zakharova, Natalia P Blokhina, Andrzej Horban, Gerlinde Teuber

Hepatology· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp).
Annemarie Berger, Tsanan Giroglou, Anke Leutz, Henry Ogbomo, Kerstin Pfaff, Gerlinde Teuber

J Clin Virol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.
Thomas Berg, Viola Weich, Gerlinde Teuber, Hartwig Klinker, Bernd Möller

Hepatology· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Donald M Jensen, Patrick Marcellin, Bradley Freilich, Pietro Andreone, Adrian Di Bisceglie, Gerlinde Teuber

Ann Intern Med· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis.
Gerlinde Teuber, Arne Schäfer, Jasmin Rimpel, Kathrin Paul, Christian Keicher

J Hepatol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, Thomas Berg, Tobias Goeser

Hepatology· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis